Breast lesion excision with needle biopsy device leaves residual carcinoma -- RSNA study.
This article was originally published in The Gray Sheet
Executive Summary
EXCISION WITH BIOPSY NEEDLE LEAVES RESIDUAL CARCINOMA in 73% of cases, researcher Laura Liberman, MD, Memorial Sloan-Kettering Cancer Center, New York City, said Dec. 2 at the Radiological Society of North America annual conference in Chicago. Reporting results of a study that used Johnson & Johnson's Mammotome percutaneous breast needle biopsy system, Liberman stated: "In this series of cancers in which percutaneous breast biopsy results in the complete removal of the mammographic lesion, surgery revealed residual carcinoma in 73%," or 11 of 15 cases, Liberman noted.